CSB Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-68917
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry/ Immunofluorescence
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
This antibody was developed against a recombinant protein corresponding to amino acids: TLSLHEITDLLETDDSIEASAIVIQPPENATAPVSDEESGDEEGGTINNLPGSLLHTAAYLIQDGSDAESDSDDPSYAPKDDSPDEVPSTFTVQQPPPSRRRKMTKILCKWKKADLTVQPVAGRVTAPPNDFFTVMRTPTE
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for CSB Antibody
Immunocytochemistry/ Immunofluorescence: CSB Antibody [NBP2-68917]
Immunocytochemistry/Immunofluorescence: CSB Antibody [NBP2-68917] - Staining of human cell line U-2 OS shows localization to nucleoplasm & nuclear bodies. Antibody staining is shown in green.Applications for CSB Antibody
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
0.25-2 ug/ml
Application Notes
Recommended conditions: Fixation/Permeabilization: PFA/Triton X-100
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS (pH 7.2) and 40% Glycerol
Preservative
0.02% Sodium Azide
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: CSB/ERCC6
Long Name
Cockayne Syndrome Protein, Type B
Alternate Names
ERCC6
Gene Symbol
ERCC6
Additional CSB/ERCC6 Products
Product Documents for CSB Antibody
Product Specific Notices for CSB Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...